The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y
1
receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y
1
receptor activity.
Carbacyclin analogs that exhibit platelet aggregation inhibition activity and other biological activites common to structurally related prostacyclins are provided.
The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y
1
receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y
1
receptor activity.